INTRODUCTION: Long-term outcomes remain unknown after stereotactic body radiation therapy (SBRT). We observed a few patients who developed disease progression late, at 5 years or more, after SBRT. In this report, we describe the characteristics of those patients with late recurrence after SBRT. METHODS: We retrospectively reviewed patients who underwent SBRT for non-small cell lung cancer with histological confirmation between January 1999 and December 2005 at our institution. During this period, 48 Gy of SBRT in four fractions at the isocenter was prescribed for all patients. RESULTS: In total, 66 patients were eligible. With a median follow-up period of 35.9 months, the 5-year overall survival and disease-free survival rates were 44.6% (95% confidence interval, 33.5-59.5%) and 33.8% (95% confidence interval, 23.6-48.4%), respectively. Of the patients, 16 survived without disease progression for 5 years or more after SBRT. Of these, four patients developed late recurrence at 76, 101, 108, and 109 months after SBRT. Three of the patients were females with adenocarcinomas; the other was a male with squamous cell carcinoma. The initial sites of recurrence were local in two patients, distant in one, and simultaneously local and distant in one. A total of two patients with local recurrence alone were still alive at 138 months after SBRT. CONCLUSIONS: The rate of late recurrence was not negligible in long-term survivors after SBRT. Our experiences indicate that long-term follow-up is needed after SBRT for non-small cell lung cancer.
INTRODUCTION: Long-term outcomes remain unknown after stereotactic body radiation therapy (SBRT). We observed a few patients who developed disease progression late, at 5 years or more, after SBRT. In this report, we describe the characteristics of those patients with late recurrence after SBRT. METHODS: We retrospectively reviewed patients who underwent SBRT for non-small cell lung cancer with histological confirmation between January 1999 and December 2005 at our institution. During this period, 48 Gy of SBRT in four fractions at the isocenter was prescribed for all patients. RESULTS: In total, 66 patients were eligible. With a median follow-up period of 35.9 months, the 5-year overall survival and disease-free survival rates were 44.6% (95% confidence interval, 33.5-59.5%) and 33.8% (95% confidence interval, 23.6-48.4%), respectively. Of the patients, 16 survived without disease progression for 5 years or more after SBRT. Of these, four patients developed late recurrence at 76, 101, 108, and 109 months after SBRT. Three of the patients were females with adenocarcinomas; the other was a male with squamous cell carcinoma. The initial sites of recurrence were local in two patients, distant in one, and simultaneously local and distant in one. A total of two patients with local recurrence alone were still alive at 138 months after SBRT. CONCLUSIONS: The rate of late recurrence was not negligible in long-term survivors after SBRT. Our experiences indicate that long-term follow-up is needed after SBRT for non-small cell lung cancer.
Authors: Nitin Ohri; Maria Werner-Wasik; Inga S Grills; José Belderbos; Andrew Hope; Di Yan; Larry L Kestin; Matthias Guckenberger; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-01 Impact factor: 7.038
Authors: Stacey Su; Walter J Scott; Mark S Allen; Gail E Darling; Paul A Decker; Robert J McKenna; Bryan F Meyers Journal: J Thorac Cardiovasc Surg Date: 2013-11-26 Impact factor: 5.209
Authors: Bing Sun; Eric D Brooks; Ritsuko Komaki; Zhongxing Liao; Melenda Jeter; Mary McAleer; Peter A Balter; James D Welsh; Michael O'Reilly; Daniel Gomez; Stephen M Hahn; Boris Sepesi; David C Rice; John V Heymach; Joe Y Chang Journal: J Thorac Oncol Date: 2017-03-01 Impact factor: 20.121
Authors: Andrew Feczko; Elizabeth McKeown; Jennifer L Wilson; Brian E Louie; Ralph W Aye; Jed A Gorden; Eric Vallières; Alexander S Farivar Journal: Can Respir J Date: 2017-02-08 Impact factor: 2.409
Authors: Anastasia Oikonomou; Farzad Khalvati; Pascal N Tyrrell; Masoom A Haider; Usman Tarique; Laura Jimenez-Juan; Michael C Tjong; Ian Poon; Armin Eilaghi; Lisa Ehrlich; Patrick Cheung Journal: Sci Rep Date: 2018-03-05 Impact factor: 4.379